New Enterprise Associates

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Retrieved on: 
Wednesday, March 13, 2024
Research, Takeda Pharmaceutical Company, IO, Biotechnology, PFM, University, Patient, Columbia University, Cowen Inc., Doctor of Philosophy, Biochemistry, New Enterprise Associates, CFA, Cancer, Texas A&M University, Pfizer, Chemical engineering, Drug development, NEA, Therapy, ADC, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
  • “We are thrilled to have Santhosh join the Pyxis Oncology board.
  • Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024," said Dr. Santhosh Palani.

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private equity, CDK2, Patient, Foresite Capital, Eli Lilly and Company, New Enterprise Associates, Therapy, OrbiMed, NEA, OncoMed, Pharmaceutical industry

(“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.

Key Points: 
  • (“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.
  • The total capital raised since the company’s founding in August 2022 is $347 million.
  • In conjunction with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors.
  • “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” said Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo.

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Gene editing, Takeda Pharmaceutical Company, Neoplasm, Investment, Pfizer, Drug discovery, University, CFA, New Enterprise Associates, Proteomics, Doctor of Philosophy, NEA, Therapy, Patient, Radiopharmaceutical, ACRV, Medicine, AP3, Texas A&M University, Chemical engineering, Columbia University, Cowen Inc., Research, PFM, Biochemistry, Pharmaceutical industry

Dr. Palani added, “Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable across drug discovery and development with significant unrealized potential -- not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Key Points: 
  • “Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • At PFM, Dr. Palani led public and private biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields.
  • Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
  • I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

CrewLAB Raises $1.6M to Democratize Data & Technology for Endurance Sports Teams

Retrieved on: 
Thursday, February 22, 2024
Apps, Applications, Technology, Other Sports, Sports, Swimming, Software, Running, Data Management, Biking, Cycling, Crew, Marist College, Athlete, Sport, New Enterprise Associates

Trusted by over 6,000 athletes and coaches across multiple countries, sports, and governing bodies , CrewLAB is quickly becoming the #1 sports team management system that "turns average teams into unstoppable crews."

Key Points: 
  • Trusted by over 6,000 athletes and coaches across multiple countries, sports, and governing bodies , CrewLAB is quickly becoming the #1 sports team management system that "turns average teams into unstoppable crews."
  • It's a shared digital team space to unite athletes and a set of tools to give coaches an edge.
  • This CrewLAB advantage is evident in several of their partner teams celebrating "best-in-10-years" performances and first-ever national championships.
  • Tom Sanford , Head Rowing Coach from Marist College shared that, “CrewLAB has exponentially increased the joy of coaching.

Propense.ai Raises $3M in Seed Funding for AI-Driven B2B Cross-Selling Platform

Retrieved on: 
Wednesday, March 6, 2024
LBMC, Psychology, Accounting, Workplace, AI, Behavior, Growth, B2B, Data science, Entrepreneurship, New Enterprise Associates, Anton Rehmann, Software as a service, Organization, Lawyer, Research, Sales

Participating investors include Operator Collective , New Enterprise Associates (NEA Angel Fund) , Florida Opportunity Fund , Glass Family Office, and angels.

Key Points: 
  • Participating investors include Operator Collective , New Enterprise Associates (NEA Angel Fund) , Florida Opportunity Fund , Glass Family Office, and angels.
  • Investors conducted thorough due diligence during the seed round, engaging with Propense.ai's clients to understand the challenges affecting the professional services industry and how the platform addresses them.
  • "We thank our clients for allowing us to build this platform and collaborating with us every step of the way," Keith said.
  • We're committed to making B2B professionals feel comfortable and supported as they embrace new sales processes that yield fruitful results for them, their firms, and their clients."

Springbig announces changes in its board of directors following the completion of its $8.0 million debt financing with a syndicate of lenders

Retrieved on: 
Monday, January 29, 2024
SBIG, Software as a service, New Enterprise Associates, Telecom, Goldman Sachs, TSX Venture Exchange, Marketing, Shawn, BOCA, Audit committee

The Company announced that Matt Sacks, Co-Managing Partner of Lightbank, and Shawn Dym, a co-lead investor in the debt financing through Shalcor Management Inc., have both joined the board of directors.

Key Points: 
  • The Company announced that Matt Sacks, Co-Managing Partner of Lightbank, and Shawn Dym, a co-lead investor in the debt financing through Shalcor Management Inc., have both joined the board of directors.
  • He started his career as a member of the Technology, Media and Telecom investment banking team at Goldman Sachs.
  • Shawn Dym is Chairman of Decibel Cannabis Company, a leading Canadian cannabis company which is listed on the TSX Venture Exchange.
  • The Company also announced that Phil Schwarz and Jon Trauben have resigned from the board of directors with effect from January 23, 2024.

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Retrieved on: 
Monday, January 22, 2024
Research, SAN, New Enterprise Associates, Prospectus, Sale, Nex Entertainment, NEA, Viking Global Investors, Security (finance)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 12.5 million shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $10.00, representing a premium of approximately 10% to ORIC’s 5-day trailing average price. The financing is expected to close on January 23, 2024, subject to customary closing conditions. ORIC anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any offering related expenses.

Key Points: 
  • The financing is expected to close on January 23, 2024, subject to customary closing conditions.
  • ORIC anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any offering related expenses.
  • The financing includes participation from new and existing institutional investors, including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, NEA, and Nextech1.
  • ORIC has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in this private placement.

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Retrieved on: 
Wednesday, January 17, 2024
Death, Commissioner, Woman, Placenta, Patient, Intensive care medicine, Pre-eclampsia, Incidence, GV, Health, LAV, Series, Seizure, Nobel, Survivor, Stroke, New Enterprise Associates, Atlas, Small RNA, Medicine, Infant, Atlas Venture, Place of birth, Risk, Food, Pregnancy, Disease, Safety, FDA, Therapy, Capital, GV (company), Venture round, Eli Lilly and Company, Population health, NEA, Diagnosis, Trial of the century, Physician, Growth, Dietary supplement

Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.

Key Points: 
  • Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.
  • It can lead to serious complications for both the mother and the baby, including multi-organ damage, seizures, and premature birth.
  • Currently, delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia.
  • Scott Johnson, M.D., Chief Executive Officer at Comanche Biopharma, commented, “We are thrilled to have the support and validation of this top-tier investor syndicate.

Sunrise AI Secures Pre-Seed Funding Led by Andrew Ng's AI Fund

Retrieved on: 
Wednesday, January 10, 2024
Greylock Partners, Spotify, Sunrise, Public policy, Forecasting, Associate, SoftBank Group, Sequoia Capital, New Enterprise Associates, University, AI, The New York Times, Schulte Roth & Zabel, Doctor of Philosophy, Columbia University, NEA, Medical device

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- Sunrise AI, a trailblazing AI-powered fintech company co-founded by Deepak Shrivastava and Xi Palazzolo , is thrilled to announce the successful closure of its pre-seed funding round led by Andrew Ng's AI Fund.

Key Points: 
  • NEW YORK, Jan. 10, 2024 /PRNewswire/ -- Sunrise AI, a trailblazing AI-powered fintech company co-founded by Deepak Shrivastava and Xi Palazzolo , is thrilled to announce the successful closure of its pre-seed funding round led by Andrew Ng's AI Fund.
  • This investment will propel Sunrise AI's mission to revolutionize credit assessment and enhance access to capital for individuals and businesses.
  • "Technology can shine new light into opaque financial systems," says Andrew Ng, Managing General Partner at AI Fund.
  • Deepak, Xi, and team have a compelling vision of using AI to create a fair and inclusive financial system for all, and AI Fund is thrilled to support Sunrise AI to realize this vision," said Andrew Ng , Managing General Partner of AI Fund, and globally recognized AI leader.

Boisson Announces Further Expansion of National Wholesale Distribution to Disrupt the $550M Non-Alcoholic Beverage Industry

Retrieved on: 
Monday, January 8, 2024
Wine & Spirits, Supermarket, Convenience Store, Restaurant, Bar, Food, Beverage, Lifestyle, Consumer, Retail, Supply Chain Management, Partnership, Energy drink, New Enterprise Associates, Millennials, NEA, Creative Artists Agency, Kaph, Omnichannel, Growth, Pernod Ricard, Leg, CAA, Saint

Boisson, the largest dedicated non-alcoholic beverage platform in the United States, is continuing to evolve the way the world drinks by expanding its national wholesale distribution through new partnerships with KeHe and LibDib, two industry leaders in on-premise and off-premise beverage distribution.

Key Points: 
  • Boisson, the largest dedicated non-alcoholic beverage platform in the United States, is continuing to evolve the way the world drinks by expanding its national wholesale distribution through new partnerships with KeHe and LibDib, two industry leaders in on-premise and off-premise beverage distribution.
  • These partnerships will further cement Boisson’s national footprint in wholesale distribution and allow it to continue leading the growth of the $550M non-alcoholic beverage category.
  • Unencumbered by traditional alcohol beverage regulations, Boisson is breaking the mold of traditional wholesale beverage distribution and taking a larger share of the food and beverage market to now include national retailers, grocery, bottle shops, and entertainment venues, in addition to traditional bars and restaurants.
  • The company will continue to leverage its retail and e-commerce platforms to be the leading omni-channel platform for consumers and non-alcoholic beverage suppliers.